<p>药明康德（NASDAQ:REGN - 获取免费报告）在周四发布的一份报告中，Truist Financial 的股票分析师将其目标价格从 798.00 美元上调至 820.00 美元，Benzinga 报道。该券商目前对这家生物制药公司的股票给予 “买入” 评级。Truist Financial 的目标价格暗示该公司当前价格有 0.76% 的潜在上涨空间。</p>
<ul>
<li>辉瑞加大对减肥药物的投资</li>
</ul>
<p>其他几位股票研究分析师最近也对 REGN 发布了报告。加拿大皇家银行将药明康德的目标价格从 704.00 美元上调至 708.00 美元，并在 10 月 29 日的报告中给予该股票 “行业表现” 评级。瑞银集团将药明康德的目标价格从 595.00 美元上调至 660.00 美元，并在 11 月 7 日的研究报告中给予该公司 “中性” 评级。花旗集团将药明康德的目标价格从 660.00 美元上调至 700.00 美元，并在 10 月 29 日的研究报告中给予该公司 “买入” 评级。汇丰银行在 11 月 24 日的研究报告中开始覆盖药明康德的股票，给予 “买入” 评级和 255.00 美元的目标价格。最后，BMO 资本市场在 12 月 4 日的研究报告中将药明康德的目标价格从 725.00 美元上调至 850.00 美元，并给予该公司 “跑赢大盘” 评级。三位股票研究分析师对该股票给予强烈买入评级，十六位给予买入评级，八位给予持有评级。根据 MarketBeat 的数据，药明康德的平均评级为 “适度买入”，共识目标价格为 791.05 美元。</p>
<p><strong>获取我们对 REGN 的最新股票分析</strong></p>
<h2>药明康德股价上涨 0.2%</h2>
<ul>
<li>5 家医疗保健公司值得关注，行业轮动已全面展开</li>
</ul>
<p>周四，REGN 股票上涨 1.51 美元，达到 813.78 美元。该公司的交易量为 434,133 股，而其平均交易量为 778,347 股。该股票的市值为 855.3 亿美元，市盈率为 19.49，市盈增长比率为 2.32，贝塔值为 0.39。该公司的 50 日移动平均线为 732.29 美元，200 日移动平均线为 624.86 美元。该公司的流动比率为 4.06，速动比率为 3.33，债务股本比率为 0.09。药明康德的 12 个月低点为 476.49 美元，12 个月高点为 816.99 美元。</p>
<p>药明康德（NASDAQ:REGN - 获取免费报告）最近在 10 月 28 日发布了季度财报。这家生物制药公司报告每股收益（EPS）为 11.83 美元，超出分析师共识预期的 9.73 美元，超出幅度为 2.10 美元。该公司在本季度的收入为 37.5 亿美元，而分析师预期为 35.7 亿美元。药明康德的净利润率为 32.13%，股本回报率为 13.76%。该公司的季度收入同比增长 0.9%。在去年同期，该公司每股收益为 12.46 美元。平均而言，股票分析师预测药明康德在本年度的每股收益将达到 35.92 美元。</p>
<h2>药明康德的内部活动</h2>
<ul>
<li>大跌者：3 只接近一年低点的股票，可能在 2025 年大幅上涨</li>
</ul>
<p>在其他消息中，副总裁 Jason Pitofsky 在 11 月 7 日的交易中出售了 431 股公司的股票。股票以平均 651.43 美元的价格出售，总交易额为 280,766.33 美元。出售完成后，该副总裁持有公司股票 4,233 股，价值约为 2,757,503.19 美元。这代表其持股减少了 9.24%。该交易在向 SEC 的法律文件中披露，文件可通过此超链接访问。此外，董事 Christine A. Poon 在 10 月 29 日的交易中出售了 6,500 股药明康德的股票。股票以平均 654.27 美元的价格出售，总交易额为 4,252,755.00 美元。交易完成后，该董事直接持有公司股票 2,352 股，价值 1,538,843.04 美元。该交易代表其持股减少了 73.43%。该销售的 SEC 文件提供了更多信息。目前，7.02% 的股票由内部人士持有。</p>
<h2>药明康德的机构交易</h2>
<p>几位大型投资者最近买入和卖出了该公司的股票。Salomon &amp; Ludwin LLC 在第三季度购买了药明康德的新股份，价值 27,000 美元。Migdal Insurance &amp; Financial Holdings Ltd.在第二季度获得了药明康德的新股份，价值约 31,000 美元。养老金保护基金董事会在第四季度获得了药明康德的新股份，价值约 31,000 美元。Caitlin John LLC 在第三季度购买了药明康德的新股份，价值约 34,000 美元。最后，Traub Capital Management LLC 在第二季度获得了药明康德的新股份，价值约 38,000 美元。83.31% 的股票由机构投资者和对冲基金持有。</p>
<h2>药明康德新闻汇总</h2>
<p>以下是本周影响药明康德的主要新闻故事：</p>
<ul>
<li>积极情绪：美国银行将 REGN 的评级从表现不佳上调至买入，并将其目标价从 627 美元提高至 860 美元，理由是关键产品的基本面改善以及多个 2026 年的催化剂。Regeneron 被美国银行上调评级</li>
<li>积极情绪：分析师情绪明显转变——Benzinga 强调至少在一家主要机构中，从表现不佳转为买入，表明分析师共识可能发生变化，吸引动量投资者。Regeneron 刚刚从表现不佳转为买入</li>
<li>积极情绪：覆盖汇总：Benzinga 的分析师调查汇编了 21 位分析师的观点，强化了近期评级上调和目标价提高对共识预期的影响。21 位分析师评估 Regeneron</li>
<li>积极情绪：分析师的上调结合空头头寸的下降可能会减少卖压，并改善投资者的风险/回报特征，根据总结这些流动性的覆盖内容。分析师上调和空头头寸下降</li>
<li>中性情绪：Zacks 强调 Regeneron 在超出预期方面的历史，并认为该公司具备再次超出收益预期的属性——这是一个潜在的催化剂，但在结果公布之前仍然是二元的。REGN 会再次超出预期吗？</li>
<li>中性情绪：几篇估值/同行比较的报道（REGN 与 ILMN，REGN 与 AVIR）为价值投资者提供了背景，但没有引入新的公司特定催化剂；对于相对价值决策有用，而非立即的价格变动。REGN 与 ILMN 比较</li>
<li>中性情绪：额外的逐一分析（例如，与 Atea 的比较）提供了信息，但不是立即的催化剂。REGN 与 AVIR 分析</li>
</ul>
<h2>Regeneron 制药公司简介</h2>
<p>(获取免费报告)</p>
<p>Regeneron Pharmaceuticals, Inc NASDAQ: REGN 是一家总部位于纽约塔里敦的美国生物技术公司，成立于 1988 年。该公司专注于发现、开发、制造和商业化用于严重医疗条件的药物。公司结合实验室研究、临床开发和内部制造，推进多个治疗领域的生物治疗管线。</p>
<p>Regeneron 以其专有的药物发现技术而闻名，包括用于生成完全人源单克隆抗体的 VelocImmune 平台。</p>
<h2>了解更多</h2>
<ul>
<li>我们更看好的五只股票，胜过 Regeneron 制药</li>
<li>特朗普时代重置？黄金可能飙升至 6000 美元的原因</li>
<li>崩盘前一个月</li>
<li>家族信托如何帮助保护你的财富</li>
<li>新法律：国会批准数字美元的设立？</li>
<li>YDES 可能是 2026 年的生物技术突破</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkVHTg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkVHTg"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在 Regeneron 制药吗？</h2>
<p>在你考虑 Regeneron 制药之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，而 Regeneron 制药并不在名单上。</p>
<p>虽然 Regeneron 制药目前在分析师中获得中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

再生元制药

<p>Truist Financial 将再生元制药（NASDAQ:REGN）的目标股价从 798.00 美元上调至 820.00 美元，维持 “买入” 评级。这表明与当前价格相比，潜在上涨幅度为 0.76%。其他分析师也调整了他们的目标，皇家银行将其设定为 708.00 美元，瑞银则为 660.00 美元。再生元最近报告每股收益为 11.83 美元，超出预期。该股票目前交易价格为 813.78 美元，市值为 855.3 亿美元，市盈率为 19.49</p>

<p>Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) had its price objective boosted by stock analysts at Truist Financial from $798.00 to $820.00 in a report released on Thursday,Benzinga reports. The brokerage currently has a &#34;buy&#34; rating on the biopharmaceutical company's stock. Truist Financial's target price would suggest a potential upside of 0.76% from the company's current price.</p>
<div class="lb-trans"><p>药明康德（NASDAQ:REGN - 获取免费报告）在周四发布的一份报告中，Truist Financial 的股票分析师将其目标价格从 798.00 美元上调至 820.00 美元，Benzinga 报道。该券商目前对这家生物制药公司的股票给予 “买入” 评级。Truist Financial 的目标价格暗示该公司当前价格有 0.76% 的潜在上涨空间。</p>
</div><ul>
<li>Pfizer Adds to Its Big Bet on Weight Loss Drugs</li>
</ul>
<div class="lb-trans"><ul>
<li>辉瑞加大对减肥药物的投资</li>
</ul>
</div><p>Several other equities research analysts also recently issued reports on REGN. Royal Bank Of Canada increased their price target on Regeneron Pharmaceuticals from $704.00 to $708.00 and gave the stock a &#34;sector perform&#34; rating in a report on Wednesday, October 29th. UBS Group boosted their price objective on Regeneron Pharmaceuticals from $595.00 to $660.00 and gave the company a &#34;neutral&#34; rating in a research report on Friday, November 7th. Citigroup lifted their price target on shares of Regeneron Pharmaceuticals from $660.00 to $700.00 and gave the company a &#34;buy&#34; rating in a research note on Wednesday, October 29th. HSBC started coverage on shares of Regeneron Pharmaceuticals in a research report on Monday, November 24th. They set a &#34;buy&#34; rating and a $255.00 price objective for the company. Finally, BMO Capital Markets boosted their price objective on shares of Regeneron Pharmaceuticals from $725.00 to $850.00 and gave the company an &#34;outperform&#34; rating in a research report on Thursday, December 4th. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and eight have assigned a Hold rating to the stock. According to MarketBeat, Regeneron Pharmaceuticals has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $791.05.</p>
<div class="lb-trans"><p>其他几位股票研究分析师最近也对 REGN 发布了报告。加拿大皇家银行将药明康德的目标价格从 704.00 美元上调至 708.00 美元，并在 10 月 29 日的报告中给予该股票 “行业表现” 评级。瑞银集团将药明康德的目标价格从 595.00 美元上调至 660.00 美元，并在 11 月 7 日的研究报告中给予该公司 “中性” 评级。花旗集团将药明康德的目标价格从 660.00 美元上调至 700.00 美元，并在 10 月 29 日的研究报告中给予该公司 “买入” 评级。汇丰银行在 11 月 24 日的研究报告中开始覆盖药明康德的股票，给予 “买入” 评级和 255.00 美元的目标价格。最后，BMO 资本市场在 12 月 4 日的研究报告中将药明康德的目标价格从 725.00 美元上调至 850.00 美元，并给予该公司 “跑赢大盘” 评级。三位股票研究分析师对该股票给予强烈买入评级，十六位给予买入评级，八位给予持有评级。根据 MarketBeat 的数据，药明康德的平均评级为 “适度买入”，共识目标价格为 791.05 美元。</p>
</div><p><strong>Get Our Latest Stock Analysis on REGN</strong></p>
<div class="lb-trans"><p><strong>获取我们对 REGN 的最新股票分析</strong></p>
</div><h2>Regeneron Pharmaceuticals Trading Up 0.2%</h2>
<div class="lb-trans"><h2>药明康德股价上涨 0.2%</h2>
</div><ul>
<li>5 Healthcare Names to Watch as Sector Rotation Is in Full Swing</li>
</ul>
<div class="lb-trans"><ul>
<li>5 家医疗保健公司值得关注，行业轮动已全面展开</li>
</ul>
</div><p>Shares of REGN stock traded up $1.51 on Thursday, reaching $813.78. The company had a trading volume of 434,133 shares, compared to its average volume of 778,347. The stock has a market cap of $85.53 billion, a PE ratio of 19.49, a PEG ratio of 2.32 and a beta of 0.39. The company has a 50-day moving average of $732.29 and a 200-day moving average of $624.86. The company has a current ratio of 4.06, a quick ratio of 3.33 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals has a 12 month low of $476.49 and a 12 month high of $816.99.</p>
<div class="lb-trans"><p>周四，REGN 股票上涨 1.51 美元，达到 813.78 美元。该公司的交易量为 434,133 股，而其平均交易量为 778,347 股。该股票的市值为 855.3 亿美元，市盈率为 19.49，市盈增长比率为 2.32，贝塔值为 0.39。该公司的 50 日移动平均线为 732.29 美元，200 日移动平均线为 624.86 美元。该公司的流动比率为 4.06，速动比率为 3.33，债务股本比率为 0.09。药明康德的 12 个月低点为 476.49 美元，12 个月高点为 816.99 美元。</p>
</div><p>Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings data on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $9.73 by $2.10. The firm had revenue of $3.75 billion during the quarter, compared to analysts' expectations of $3.57 billion. Regeneron Pharmaceuticals had a net margin of 32.13% and a return on equity of 13.76%. The business's revenue for the quarter was up .9% on a year-over-year basis. During the same quarter in the previous year, the company earned $12.46 earnings per share. On average, equities analysts forecast that Regeneron Pharmaceuticals will post 35.92 earnings per share for the current year.</p>
<div class="lb-trans"><p>药明康德（NASDAQ:REGN - 获取免费报告）最近在 10 月 28 日发布了季度财报。这家生物制药公司报告每股收益（EPS）为 11.83 美元，超出分析师共识预期的 9.73 美元，超出幅度为 2.10 美元。该公司在本季度的收入为 37.5 亿美元，而分析师预期为 35.7 亿美元。药明康德的净利润率为 32.13%，股本回报率为 13.76%。该公司的季度收入同比增长 0.9%。在去年同期，该公司每股收益为 12.46 美元。平均而言，股票分析师预测药明康德在本年度的每股收益将达到 35.92 美元。</p>
</div><h2>Insider Activity at Regeneron Pharmaceuticals</h2>
<div class="lb-trans"><h2>药明康德的内部活动</h2>
</div><ul>
<li>Big Dippers: 3 Stocks Near 1-Year Lows That Could Surge in 2025</li>
</ul>
<div class="lb-trans"><ul>
<li>大跌者：3 只接近一年低点的股票，可能在 2025 年大幅上涨</li>
</ul>
</div><p>In other news, VP Jason Pitofsky sold 431 shares of the company's stock in a transaction that occurred on Friday, November 7th. The shares were sold at an average price of $651.43, for a total transaction of $280,766.33. Following the completion of the sale, the vice president owned 4,233 shares of the company's stock, valued at approximately $2,757,503.19. This represents a 9.24% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Christine A. Poon sold 6,500 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Wednesday, October 29th. The shares were sold at an average price of $654.27, for a total transaction of $4,252,755.00. Following the completion of the transaction, the director directly owned 2,352 shares in the company, valued at $1,538,843.04. This trade represents a 73.43% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 7.02% of the stock is currently owned by insiders.</p>
<div class="lb-trans"><p>在其他消息中，副总裁 Jason Pitofsky 在 11 月 7 日的交易中出售了 431 股公司的股票。股票以平均 651.43 美元的价格出售，总交易额为 280,766.33 美元。出售完成后，该副总裁持有公司股票 4,233 股，价值约为 2,757,503.19 美元。这代表其持股减少了 9.24%。该交易在向 SEC 的法律文件中披露，文件可通过此超链接访问。此外，董事 Christine A. Poon 在 10 月 29 日的交易中出售了 6,500 股药明康德的股票。股票以平均 654.27 美元的价格出售，总交易额为 4,252,755.00 美元。交易完成后，该董事直接持有公司股票 2,352 股，价值 1,538,843.04 美元。该交易代表其持股减少了 73.43%。该销售的 SEC 文件提供了更多信息。目前，7.02% 的股票由内部人士持有。</p>
</div><h2>Institutional Trading of Regeneron Pharmaceuticals</h2>
<div class="lb-trans"><h2>药明康德的机构交易</h2>
</div><p>Several large investors have recently bought and sold shares of the business. Salomon &amp; Ludwin LLC bought a new stake in Regeneron Pharmaceuticals during the third quarter valued at $27,000. Migdal Insurance &amp; Financial Holdings Ltd. acquired a new position in shares of Regeneron Pharmaceuticals in the 2nd quarter valued at about $31,000. Board of the Pension Protection Fund acquired a new position in shares of Regeneron Pharmaceuticals in the 4th quarter valued at about $31,000. Caitlin John LLC bought a new stake in shares of Regeneron Pharmaceuticals during the 3rd quarter valued at about $34,000. Finally, Traub Capital Management LLC acquired a new stake in Regeneron Pharmaceuticals during the second quarter worth approximately $38,000. 83.31% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>几位大型投资者最近买入和卖出了该公司的股票。Salomon &amp; Ludwin LLC 在第三季度购买了药明康德的新股份，价值 27,000 美元。Migdal Insurance &amp; Financial Holdings Ltd.在第二季度获得了药明康德的新股份，价值约 31,000 美元。养老金保护基金董事会在第四季度获得了药明康德的新股份，价值约 31,000 美元。Caitlin John LLC 在第三季度购买了药明康德的新股份，价值约 34,000 美元。最后，Traub Capital Management LLC 在第二季度获得了药明康德的新股份，价值约 38,000 美元。83.31% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>Regeneron Pharmaceuticals News Roundup</h2>
<div class="lb-trans"><h2>药明康德新闻汇总</h2>
</div><p>Here are the key news stories impacting Regeneron Pharmaceuticals this week:</p>
<div class="lb-trans"><p>以下是本周影响药明康德的主要新闻故事：</p>
</div><ul>
<li>Positive Sentiment: Bank of America upgraded REGN to Buy from Underperform and raised its price objective to $860 (from $627), citing improving fundamentals across key products and multiple 2026 catalysts. Regeneron upgraded by Bank of America</li>
<li>Positive Sentiment: Analyst sentiment has shifted noticeably — Benzinga highlights a move from Underperform to Buy at least at one major shop, signaling a potential change in the analyst consensus that can attract momentum investors. Regeneron just moved from underperform to buy</li>
<li>Positive Sentiment: Coverage roundup: Benzinga’s analyst survey piece compiles views from 21 analysts, reinforcing that the recent rating upgrades and higher targets are influencing consensus expectations. 21 Analysts Assess Regeneron</li>
<li>Positive Sentiment: Analyst upgrades combined with a drop in short interest may reduce selling pressure and improve the risk/reward profile for investors, according to coverage summarizing these flows. Analyst upgrades and short-interest drop</li>
<li>Neutral Sentiment: Zacks highlights Regeneron’s history of beating estimates and argues the company has the attributes to deliver another earnings beat — a potential catalyst, but one that remains binary until results are posted. Will REGN beat estimates again?</li>
<li>Neutral Sentiment: Several valuation/peer-compare stories (REGN vs ILMN, REGN vs AVIR) provide context for value investors but don’t introduce new company-specific catalysts; useful for relative-value decisions rather than immediate price moves. REGN vs ILMN comparison</li>
<li>Neutral Sentiment: Additional head‑to‑head analyses (e.g., vs. Atea) are informational but not immediate catalysts. REGN vs AVIR analysis</li>
</ul>
<div class="lb-trans"><ul>
<li>积极情绪：美国银行将 REGN 的评级从表现不佳上调至买入，并将其目标价从 627 美元提高至 860 美元，理由是关键产品的基本面改善以及多个 2026 年的催化剂。Regeneron 被美国银行上调评级</li>
<li>积极情绪：分析师情绪明显转变——Benzinga 强调至少在一家主要机构中，从表现不佳转为买入，表明分析师共识可能发生变化，吸引动量投资者。Regeneron 刚刚从表现不佳转为买入</li>
<li>积极情绪：覆盖汇总：Benzinga 的分析师调查汇编了 21 位分析师的观点，强化了近期评级上调和目标价提高对共识预期的影响。21 位分析师评估 Regeneron</li>
<li>积极情绪：分析师的上调结合空头头寸的下降可能会减少卖压，并改善投资者的风险/回报特征，根据总结这些流动性的覆盖内容。分析师上调和空头头寸下降</li>
<li>中性情绪：Zacks 强调 Regeneron 在超出预期方面的历史，并认为该公司具备再次超出收益预期的属性——这是一个潜在的催化剂，但在结果公布之前仍然是二元的。REGN 会再次超出预期吗？</li>
<li>中性情绪：几篇估值/同行比较的报道（REGN 与 ILMN，REGN 与 AVIR）为价值投资者提供了背景，但没有引入新的公司特定催化剂；对于相对价值决策有用，而非立即的价格变动。REGN 与 ILMN 比较</li>
<li>中性情绪：额外的逐一分析（例如，与 Atea 的比较）提供了信息，但不是立即的催化剂。REGN 与 AVIR 分析</li>
</ul>
</div><h2>Regeneron Pharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>Regeneron 制药公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>Regeneron Pharmaceuticals, Inc NASDAQ: REGN is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.</p>
<div class="lb-trans"><p>Regeneron Pharmaceuticals, Inc NASDAQ: REGN 是一家总部位于纽约塔里敦的美国生物技术公司，成立于 1988 年。该公司专注于发现、开发、制造和商业化用于严重医疗条件的药物。公司结合实验室研究、临床开发和内部制造，推进多个治疗领域的生物治疗管线。</p>
</div><p>Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.</p>
<div class="lb-trans"><p>Regeneron 以其专有的药物发现技术而闻名，包括用于生成完全人源单克隆抗体的 VelocImmune 平台。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than Regeneron Pharmaceuticals</li>
<li>Trump Era Reset? Why Gold Could Explode to $6,000</li>
<li>A month before the crash</li>
<li>How a Family Trust May Be Able To Help Preserve Your Wealth</li>
<li>NEW LAW: Congress Approves Setup For Digital Dollar?</li>
<li>YDES Could Be 2026's Biotech Breakthrough</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过 Regeneron 制药</li>
<li>特朗普时代重置？黄金可能飙升至 6000 美元的原因</li>
<li>崩盘前一个月</li>
<li>家族信托如何帮助保护你的财富</li>
<li>新法律：国会批准数字美元的设立？</li>
<li>YDES 可能是 2026 年的生物技术突破</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkVHTg" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&amp;Symbol=REGN"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Regeneron Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在 Regeneron 制药吗？</h2>
</div><p>Before you consider Regeneron Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Regeneron 制药之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Regeneron Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，而 Regeneron 制药并不在名单上。</p>
</div><p>While Regeneron Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Regeneron 制药目前在分析师中获得中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

再生元制药（NASDAQ:REGN）在 Truist Financial 被设定了新的目标价为 820.00 美元